TIANYU PHARM: Wholly-owned subsidiary's raw materials obtained CEP certification
On the evening of July 28, TIANYU PHARM announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., received the European Pharmacopoeia suitability certification for the active pharmaceutical ingredient Sitagliptin Phosphate issued by the European Medicines Agency. Sitagliptin Phosphate is an antidiabetic medication that helps control blood sugar levels and is primarily used for the treatment of type 2 diabetes
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments